1. Home
  2. REAX vs ABUS Comparison

REAX vs ABUS Comparison

Compare REAX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Real Brokerage Inc.

REAX

The Real Brokerage Inc.

HOLD

Current Price

$2.74

Market Cap

792.1M

Sector

N/A

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$3.95

Market Cap

888.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REAX
ABUS
Founded
2018
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
792.1M
888.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REAX
ABUS
Price
$2.74
$3.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$5.90
$5.00
AVG Volume (30 Days)
1.6M
2.1M
Earning Date
03-04-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,813,907,000.00
$14,606,000.00
Revenue This Year
$57.12
$125.30
Revenue Next Year
$20.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
65.60
116.64
52 Week Low
$2.55
$2.71
52 Week High
$5.65
$5.10

Technical Indicators

Market Signals
Indicator
REAX
ABUS
Relative Strength Index (RSI) 29.49 44.23
Support Level $2.55 $3.85
Resistance Level $3.28 $4.26
Average True Range (ATR) 0.20 0.30
MACD -0.07 0.01
Stochastic Oscillator 16.27 46.82

Price Performance

Historical Comparison
REAX
ABUS

About REAX The Real Brokerage Inc.

The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: